DK3541784T5 - Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission - Google Patents
Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission Download PDFInfo
- Publication number
- DK3541784T5 DK3541784T5 DK17807779.8T DK17807779T DK3541784T5 DK 3541784 T5 DK3541784 T5 DK 3541784T5 DK 17807779 T DK17807779 T DK 17807779T DK 3541784 T5 DK3541784 T5 DK 3541784T5
- Authority
- DK
- Denmark
- Prior art keywords
- modulators
- derivatives useful
- azetidine derivatives
- novel azetidine
- cortical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16199545 | 2016-11-18 | ||
| PCT/EP2017/079666 WO2018091687A1 (en) | 2016-11-18 | 2017-11-17 | Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK3541784T3 DK3541784T3 (en) | 2023-10-23 |
| DK3541784T5 true DK3541784T5 (da) | 2024-09-16 |
Family
ID=57348567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17807779.8T DK3541784T5 (da) | 2016-11-18 | 2017-11-17 | Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10875829B1 (enExample) |
| EP (1) | EP3541784B1 (enExample) |
| JP (1) | JP6990702B2 (enExample) |
| CN (1) | CN109963834B (enExample) |
| DK (1) | DK3541784T5 (enExample) |
| ES (1) | ES2962865T3 (enExample) |
| FI (1) | FI3541784T3 (enExample) |
| PL (1) | PL3541784T3 (enExample) |
| PT (1) | PT3541784T (enExample) |
| WO (1) | WO2018091687A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112198237B (zh) * | 2020-05-28 | 2021-08-06 | 扬子江药业集团广州海瑞药业有限公司 | 一种盐酸奈康唑杂质检测控制分析方法 |
| EP4739654A1 (en) | 2023-07-06 | 2026-05-13 | Integrative Research Laboratories Sweden AB | Pharmaceutically acceptable salts of 3-(2,3-difluorophenoxy)azetidine and uses thereof |
| WO2025008506A1 (en) | 2023-07-06 | 2025-01-09 | Integrative Research Laboratories Sweden Ab | 3-(2,3-difluorophenoxy)azetidine, or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of pathological apathy |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1638939A2 (en) * | 2003-06-24 | 2006-03-29 | Neurosearch A/S | Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| AP2007004047A0 (en) | 2005-01-20 | 2007-06-30 | Pfizer Ltd | Substituted triazole derivatives as oxtocin antagonists |
| WO2007148185A2 (en) | 2006-06-21 | 2007-12-27 | Pfizer Products Inc. | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors |
| WO2010022055A2 (en) | 2008-08-20 | 2010-02-25 | Amgen Inc. | Inhibitors of voltage-gated sodium channels |
| EP2367785B1 (en) | 2008-11-24 | 2014-10-15 | Integrative Research Laboratories Sweden AB | Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission |
| JP5716202B2 (ja) | 2008-11-24 | 2015-05-13 | インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー | 皮質のカテコールアミン作動性神経伝達のモジュレーターとしての３−フェニル−３−メトキシピロリジン誘導体 |
| JP2012515760A (ja) | 2009-01-20 | 2012-07-12 | ファイザー・インク | 置換ピラジノンアミド |
| TWI404721B (zh) * | 2009-01-26 | 2013-08-11 | Pfizer | 胺基－雜環化合物 |
| JP2013519732A (ja) * | 2010-02-17 | 2013-05-30 | アムジエン・インコーポレーテツド | 疼痛治療のためのナトリウムチャンネル阻害薬としてのアリールカルボキサミド誘導体 |
| EP2718295A1 (en) | 2011-06-07 | 2014-04-16 | Pfizer Inc | Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors |
| KR101273566B1 (ko) | 2011-09-05 | 2013-06-11 | 한국과학기술연구원 | 신규한 아제티딘 유도체 및 이를 함유하는 항우울제 조성물 |
| CN104093720B (zh) * | 2012-01-26 | 2017-04-12 | H.隆德贝克有限公司 | 具有咪唑并三嗪酮骨架的pde9抑制剂 |
| KR101894681B1 (ko) * | 2014-08-27 | 2018-09-04 | 에프. 호프만-라 로슈 아게 | Taar 리간드로서의 치환된 아제티딘 유도체 |
| US10040759B2 (en) * | 2014-11-05 | 2018-08-07 | Dart Neuroscience (Cayman) Ltd. | Substituted azetidinyl compounds as GlyT1 inhibitors |
| EP3297987B1 (en) * | 2015-05-20 | 2019-05-15 | Integrative Research Laboratories Sweden AB | Novel azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission |
| CN108026030B (zh) | 2015-09-18 | 2020-10-09 | 正大天晴药业集团股份有限公司 | 一种氘代化合物的制备方法 |
| TWI752098B (zh) * | 2016-10-10 | 2022-01-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
-
2017
- 2017-11-17 ES ES17807779T patent/ES2962865T3/es active Active
- 2017-11-17 FI FIEP17807779.8T patent/FI3541784T3/fi active
- 2017-11-17 PL PL17807779.8T patent/PL3541784T3/pl unknown
- 2017-11-17 US US16/461,086 patent/US10875829B1/en active Active
- 2017-11-17 EP EP17807779.8A patent/EP3541784B1/en active Active
- 2017-11-17 DK DK17807779.8T patent/DK3541784T5/da active
- 2017-11-17 JP JP2019525851A patent/JP6990702B2/ja active Active
- 2017-11-17 CN CN201780069687.6A patent/CN109963834B/zh active Active
- 2017-11-17 PT PT178077798T patent/PT3541784T/pt unknown
- 2017-11-17 WO PCT/EP2017/079666 patent/WO2018091687A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019535715A (ja) | 2019-12-12 |
| CN109963834B (zh) | 2023-04-14 |
| US10875829B1 (en) | 2020-12-29 |
| CN109963834A (zh) | 2019-07-02 |
| PL3541784T3 (pl) | 2024-03-11 |
| ES2962865T3 (es) | 2024-03-21 |
| WO2018091687A1 (en) | 2018-05-24 |
| PT3541784T (pt) | 2023-11-22 |
| EP3541784A1 (en) | 2019-09-25 |
| DK3541784T3 (en) | 2023-10-23 |
| EP3541784B1 (en) | 2023-09-13 |
| JP6990702B2 (ja) | 2022-01-13 |
| FI3541784T3 (fi) | 2023-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR25C1013I1 (fr) | Macrocycles de diaryle en tant que modulateurs de protéines kinases | |
| LT3728238T (lt) | Sulfonilkarbamido dariniai kaip nlrp3 uždegimo moduliatoriai | |
| PL3507418T3 (pl) | Sposoby biopochodnej derywatyzacji powierzchni celulozowych | |
| EP3347372A4 (en) | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 | |
| DK3331876T3 (da) | Modulators of ror-gamma | |
| EP3509581A4 (en) | FORMULATIONS OF (R | |
| FR3021533B1 (fr) | Composition cosmetique de type gel | |
| HUE054009T2 (hu) | Szubsztituált tetrahidrokinolinon vegyületek ROR gamma modulátorként | |
| PT3457851T (pt) | Derivados de sobetiroma | |
| PT3645518T (pt) | Síntese de omecamtiv mecarbil | |
| EP3360010A4 (en) | BI PHOTONS WITH VOTABLE SOURCE | |
| EP3379139A4 (en) | LAMPHOLDER | |
| EP3430816A4 (en) | FRAME TRANSMISSION | |
| IL266505B (en) | Heterocyclic modulators of lipid synthesis | |
| HUE049606T2 (hu) | Eljárás flavonoid inklúziós vegyületek elõállítására | |
| PL3625224T3 (pl) | Pochodne n-podstawionego indolu | |
| BR112016026046A2 (pt) | Uso de compostos de tienotriazolodiazepina | |
| EP3688095A4 (en) | POLYCARBONATE COMPOSITION | |
| FR3023290B1 (fr) | Derives de flavaglines | |
| IL250613B (en) | Substituted bicyclic compounds | |
| EP3277701A4 (en) | SYNTHESIS OF DESOSAMINES | |
| PL3717523T3 (pl) | Sposób modyfikacji ldpe | |
| LT3347349T (lt) | Fluorindolo dariniai kaip muskarininio m1 receptoriaus teigiami alosteriniai moduliatoriai | |
| EP3288549A4 (en) | GUANFACINE LIQUID ORAL COMPOSITIONS | |
| EP3171860C0 (en) | SOLID ORAL FORMULATION OF FENRETINIDE |